CITELINE Japan Award 2024 Biotech company of the year ファイナリストに選出

当社とエーザイの共同創出品E7386についてESMO(欧州臨床腫瘍学会)年次総会においてエーザイが発表

TOKYO, Japan, 9 September 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the interim analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate ( “lenvatinib”) will be presented...

東京オフィス開設のご案内

We are pleased to announce the establishment of PRISM BioLab Co., Ltd. Tokyo office. The office was officially opened on September 2, 2024 and will serve as a base for our business and administrative functions, for enhanced communications with our investors and partners, and to enable more effective business decisions. We sincerely appreciate the continued...

東京証券取引所グロース市場へ新規上場のお知らせ

PRISM BioLab Corporation is pleased to announce its initial listing on the Tokyo Stock Exchange Growth Market today. We would like to take this opportunity to express our sincere gratitude to all our stakeholders for their unwavering support and cooperation. For more details regarding our new listing, please visit the Tokyo Stock Exchange website. https://www.jpx.co.jp/listing/stocks/new/index.html...

PRISM BioLab、イーライリリー・アンド・カンパニーとsantec Holdingsから15億円の資金調達実施のお知らせ

TOKYO, Japan, 24 Jan 2024: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced a 1.5 billion yen ($10.3M) fundraise. Funds will be used to refine PRISM’s proprietary PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipeline of...

Scroll to top
jaJapanese